HLA-DQA2: A Promising Drug Target / Biomarker (G3118)

Target Name: HLA-DQA2

NCBI ID: G3118

HLA-DQA2

HLA-DQA2: A Promising Drug Target / Biomarker

HLA-DQA2 is a human leukocyte antigen (HLA) gene that is located on chromosome 6p21. It is a member of the major histocompatibility complex (MHC) class I molecules, which are responsible for presenting antigens from the immune system to T-cells. HLA-DQA2 is a potential drug target and has been identified as a biomarker for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

Diseases and Their Relationship to HLA-DQA2

HLA-DQA2 has been implicated in the development and progression of several diseases. One of the most well-known associations is with cancer. Studies have shown that individuals with certain HLA-DQA2 variants are at an increased risk of developing melanoma, a type of skin cancer. Additionally, HLA-DQA2 has been linked to the development of several autoimmune disorders, including rheumatoid arthritis, lupus, and psoriasis.

Another potential application of HLA-DQA2 as a drug target is in the treatment of neurodegenerative diseases. The neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and can result in a range of symptoms, including cognitive decline, tremors, and motor symptoms.

HLA-DQA2 is a potential drug target because it is involved in the immune response and has been shown to play a role in the development and progression of these diseases. By targeting HLA-DQA2, researchers and clinicians may be able to develop new treatments for neurodegenerative diseases and improve the quality of life for patients.

Methods

To study HLA-DQA2, researchers have used a variety of techniques, including PCR, qRT-PCR, and mass spectrometry. These techniques allow researchers to detect and measure the expression of HLA-DQA2 in a variety of cell types and to identify changes in gene expression that may be associated with the development and progression of diseases.

One of the challenges in studying HLA-DQA2 is the complexity of its role in the immune response. HLA-DQA2 is a key member of the MHC class I molecules, which are responsible for presenting antigens from the immune system to T-cells. This means that HLA-DQA2 is involved in the immune response and may be a target for drugs that disrupt this function.

Another challenge is the diversity of the HLA-DQA2 gene and the complexity of its role in different diseases. HLA-DQA2 variants have been identified that are associated with an increased risk of cancer, autoimmune disorders, and neurodegenerative diseases. This suggests that HLA-DQA2 may be a useful biomarker for these diseases and that targeting this protein may be a promising strategy for the development of new treatments.

Conclusion

HLA-DQA2 is a protein that is involved in the immune response and has been implicated in the development and progression of several diseases. As a potential drug target, HLA-DQA2 has the potential to improve the treatment options for neurodegenerative diseases and improve the quality of life for patients. Further research is needed to fully understand the role of HLA-DQA2 in the immune response and to develop effective treatments for these diseases.

Protein Name: Major Histocompatibility Complex, Class II, DQ Alpha 2

Functions: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading

The "HLA-DQA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DQA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets